82 FR 44820 - Notice of Non-Competitive, Supplemental Funding Award for Ryan White HIV/AIDS Program, Special Projects of National Significance
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration Federal Register Volume 82, Issue 185 (September 26, 2017)
Health Resources and Services Administration
Federal Register Volume 82, Issue 185 (September 26, 2017)
| Page Range | 44820-44821 | |
| FR Document | 2017-20544 |
[Federal Register Volume 82, Number 185 (Tuesday, September 26, 2017)] [Notices] [Pages 44820-44821] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2017-20544] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Health Resources and Services Administration Notice of Non-Competitive, Supplemental Funding Award for Ryan White HIV/AIDS Program, Special Projects of National Significance AGENCY: Health Resources and Services Administration (HRSA), HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: This non-competitive award will provide Secretary's Minority AIDS Initiative Fund (SMAIF) supplemental funding to the Jurisdictional Approach to Curing Hepatitis C among HIV/HCV Coinfected People of Color--Evaluation and Technical Assistance Center (ETAC), RAND Corporation. This supplemental funding will allow RAND Corporation to provide evaluation and technical assistance to cooperative agreement recipients and subrecipient clinical sites under HRSA-17-047 Curing Hepatitis C among People of Color Living with HIV. SUPPLEMENTARY INFORMATION: Intended Recipient of the Award: RAND Corporation (U90HA30519). Amount of Non-Competitive Award: Up to $250,000 per year for 3 years (pending availability of future year funding). Period of Funding: September 30, 2017, through September 29, 2020. CFDA Number: No. 93.928. Authority: The Consolidated Appropriations Act, 2017 (Pub. L. 115- 31), Division H, Title II. Justification: In fiscal year (FY) 2016, the SMAIF Curing Hepatitis C among People of Color Living with HIV initiative was launched through three funding opportunities: (1) Jurisdictional Approach to Curing Hepatitis C among HIV/HCV Co-infected People of Color--Jurisdictional Sites (HRSA-16-189) and (2) Jurisdictional Approach to Curing Hepatitis C among HIV/HCV Coinfected People of Color--State Health Departments Coordinating Center (HRSA-16-195) to provide HIV primary medical care to low income, uninsured, and underserved people living with both HIV and hepatitis C virus (HCV); and (3) Jurisdictional Approach to Curing Hepatitis C among HIV/HCV Coinfected People of Color--ETAC (HRSA-16- 188) to provide evaluation and technical assistance to the funded sites. In FY17, HRSA-17-047 was announced to improve HCV prevention and care; improve coordination to linkage and retention in care; and enhance capacity of health department [[Page 44821]] surveillance systems to monitor HIV/HCV coinfections among low-income or underinsured, racial and ethnic minority populations. HRSA-17-047 recipients and subrecipients will require similar evaluation and technical assistance in order to meet the program's goals and objectives. Supplemental funding to the existing ETAC is a cost effective and efficient solution that will leverage RAND Corporation's currently funded infrastructure to include the additional sites funded under HRSA-17-047. Further, this supplemental funding will leverage RAND's current work by combining and comparing evaluation results across all jurisdictions from both initiatives and facilitate the streamlining and integration of processes and technical assistance. Supplemental funding will also provide opportunities for RAND Corporation to create joint learning networks and build on lessons learned from the initial cohort of jurisdictional sites currently in the second year of implementation. Not issuing this award would result in a lack of evaluation and technical assistance for HRSA-17-047 recipients and subrecipients, which is critical to achieving the initiative's goal to cure HCV among HIV/HCV coinfected people of color. FOR FURTHER INFORMATION CONTACT: Mr. Adan Cajina, Chief, Demonstration Evaluation Branch, Office of Training and Capacity Development, Division of HIV Domestic Programs, HIV/AIDS Bureau, HRSA, 5600 Fishers Lane, 09N108, Rockville, MD 20857, Phone: (301) 443-3180, Email: [email protected]. Dated: September 19, 2017. George Sigounas, Administrator. [FR Doc. 2017-20544 Filed 9-25-17; 8:45 am] BILLING CODE 4165-15-P
![44820 Federal Register / Vol. 82, No. 185 / Tuesday, September 26, 2017 / Notices
The review panel will make selections Scalability DEPARTMENT OF HEALTH AND
based upon the following criteria: HUMAN SERVICES
• How costly was the intervention in
Phase 1 a real-world setting? How likely are cost Health Resources and Services
Accessibility efficiencies for program delivery at Administration
• Is the proposed intervention easily greater scale? Can the technology be
used in existing platforms? Notice of Non-Competitive,
utilized by families of diverse economic, Supplemental Funding Award for Ryan
social, and cultural backgrounds? Is it Additional Information White HIV/AIDS Program, Special
functional across disciplines/users?
Projects of National Significance
General Conditions:
Measurability
• HRSA reserves the right to cancel, AGENCY: Health Resources and Services
• How easily will the proposed Administration (HRSA), HHS.
suspend, and/or modify the contest, or
intervention be evaluated in order to ACTION: Notice.
determine its efficacy (in both lab any part of it, for any reason, at HRSA’s
testing and in the real world)? Is the sole discretion.
SUMMARY: This non-competitive award
proposed intervention measurable • The interventions submitted across will provide Secretary’s Minority AIDS
among various audiences? all phases should not use the HHS or Initiative Fund (SMAIF) supplemental
Sustainability HRSA logos or official seals in the funding to the Jurisdictional Approach
submission, and must not claim to Curing Hepatitis C among HIV/HCV
• Does the proposed intervention endorsement. Coinfected People of Color—Evaluation
compel users to utilize the technology and Technical Assistance Center
often and/or for long periods of time? Intellectual Property
(ETAC), RAND Corporation. This
Does it fit into daily life? Is it fun to use? supplemental funding will allow RAND
• Each entrant retains full ownership
Impact and title in and to their submission. Corporation to provide evaluation and
• Does the applicant present a theory Entrants expressly reserve all technical assistance to cooperative
or explanation of how the proposed intellectual property rights not agreement recipients and subrecipient
intervention would result in concrete expressly granted under the challenge clinical sites under HRSA–17–047
change? Curing Hepatitis C among People of
agreement.
Color Living with HIV.
Phase 2 • By participating in the challenge, SUPPLEMENTARY INFORMATION:
each entrant hereby irrevocably grants Intended Recipient of the Award:
Impact
to HRSA a limited, non-exclusive, RAND Corporation (U90HA30519).
• How did the intervention impact royalty-free, worldwide license and Amount of Non-Competitive Award:
outcomes for providers and patients? right to reproduce, publically perform, Up to $250,000 per year for 3 years
What did data show? publically display, and use the (pending availability of future year
Evidence Base submission for internal HHS business funding).
• Is the intervention grounded in and to the extent necessary to Period of Funding: September 30,
existing science related to improving administer the challenge, and to 2017, through September 29, 2020.
health care and related services for publically perform and publically CFDA Number: No. 93.928.
pregnant women? display the submission, including, Authority: The Consolidated
without limitation, for advertising and Appropriations Act, 2017 (Pub. L. 115–
Sustainability promotional purposes relating to the 31), Division H, Title II.
• Was the intervention compelling to challenge. Justification: In fiscal year (FY) 2016,
users and did it encourage users to use the SMAIF Curing Hepatitis C among
• Record Retention and FOIA: All People of Color Living with HIV
the technology often? Did users want to
materials submitted to HRSA as part of initiative was launched through three
continuously engage with the
a submission become HRSA records and funding opportunities: (1) Jurisdictional
technology?
cannot be returned. Any confidential Approach to Curing Hepatitis C among
Implementation commercial information contained in a HIV/HCV Co-infected People of Color—
• How feasible is the intervention? submission should be designated at the Jurisdictional Sites (HRSA–16–189) and
How much support for implementation time of submission. Participants will be (2) Jurisdictional Approach to Curing
will the intervention require (estimated notified of any Freedom of Information Hepatitis C among HIV/HCV Coinfected
financial and time commitment)? Act requests for their submissions in People of Color—State Health
accordance with 45 CFR 5.65. Departments Coordinating Center
Phase 3
Dated: September 19, 2017. (HRSA–16–195) to provide HIV primary
Impact medical care to low income, uninsured,
George Sigounas,
• How effective was the intervention and underserved people living with
Administrator. both HIV and hepatitis C virus (HCV);
when implemented at scale? Did the
[FR Doc. 2017–20539 Filed 9–25–17; 8:45 am] and (3) Jurisdictional Approach to
impacts on users from Phase 2 remain
consistent? BILLING CODE 4165–15–P Curing Hepatitis C among HIV/HCV
Coinfected People of Color—ETAC
Implementation (HRSA–16–188) to provide evaluation
• How feasible was the intervention and technical assistance to the funded
on a larger scale? How much support for sites. In FY17, HRSA–17–047 was
implementation did the model require announced to improve HCV prevention
(financial and time commitment)? How and care; improve coordination to
challenging was the actual program linkage and retention in care; and
implementation? enhance capacity of health department
VerDate Sep<11>2014 18:28 Sep 25, 2017 Jkt 241001 PO 00000 Frm 00062 Fmt 4703 Sfmt 4703 E:\FR\FM\26SEN1.SGM 26SEN1](https://thefederalregister.org/doc/82_FR_45005/page/1.svg)
![Federal Register / Vol. 82, No. 185 / Tuesday, September 26, 2017 / Notices 44821
surveillance systems to monitor HIV/ reasonable accommodations, should DEPARTMENT OF HEALTH AND
HCV coinfections among low-income or notify the Contact Person listed below HUMAN SERVICES
underinsured, racial and ethnic in advance of the meeting. The meeting
minority populations. HRSA–17–047 will also be videocast and can be National Institutes of Health
recipients and subrecipients will require accessed from the NIH Videocasting and
similar evaluation and technical National Heart, Lung, and Blood
Podcasting Web site (http://
assistance in order to meet the Institute; Notice of Closed Meeting
videocast.nih.gov/).
program’s goals and objectives. Pursuant to section 10(d) of the
Supplemental funding to the existing Name of Committee: Frederick National
Laboratory Advisory Committee to the Federal Advisory Committee Act, as
ETAC is a cost effective and efficient amended, notice is hereby given of a
solution that will leverage RAND National Cancer Institute
Date: October 30, 2017. meeting of the NHLBI Special Emphasis
Corporation’s currently funded Panel.
infrastructure to include the additional Time: 9:00 a.m. to 5:00 p.m.
Agenda: Ongoing and new activities at the The meeting will be closed to the
sites funded under HRSA–17–047. public in accordance with the
Further, this supplemental funding will Frederick National Laboratory for Cancer
Research. provisions set forth in sections
leverage RAND’s current work by 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
combining and comparing evaluation Place: National Institutes of Health, 31
Center Drive, Building 31, Wing C; 6th Floor, as amended. The grant applications and
results across all jurisdictions from both the discussions could disclose
Conference Room 10, Bethesda, MD 20892.
initiatives and facilitate the streamlining
Contact Person: Caron A. Lyman, Ph.D. confidential trade secrets or commercial
and integration of processes and
Executive Secretary, National Cancer property such as patentable material,
technical assistance. Supplemental
Institute, National Institutes of Health, 9609 and personal information concerning
funding will also provide opportunities
Medical Center Drive, Room 7W–126, individuals associated with the grant
for RAND Corporation to create joint
Bethesda, MD 20892, 240–276–6348 applications, the disclosure of which
learning networks and build on lessons
lymanc@mail.nih.gov. would constitute a clearly unwarranted
learned from the initial cohort of
Any interested person may file written invasion of personal privacy.
jurisdictional sites currently in the
second year of implementation. Not comments with the committee by forwarding Name of Committee: National Heart, Lung,
issuing this award would result in a lack the statement to the Contact Person listed on and Blood Institute Special Emphasis Panel;
of evaluation and technical assistance this notice. The statement should include the Grant Review for NHLBI K Award Recipients.
name, address, telephone number and when Date: October 17, 2017.
for HRSA–17–047 recipients and
applicable, the business or professional Time: 12:00 p.m. to 4:00 p.m.
subrecipients, which is critical to Agenda: To review and evaluate grant
achieving the initiative’s goal to cure affiliation of the interested person.
In the interest of security, NIH has applications.
HCV among HIV/HCV coinfected people Place: National Institutes of Health, 6701
of color. instituted stringent procedures for entrance
Rockledge Drive, Suite 7202, Bethesda, MD
onto the NIH campus. All visitor vehicles, 20892 (Telephone Conference Call).
FOR FURTHER INFORMATION CONTACT: Mr.
including taxicabs, hotel, and airport shuttles Contact Person: Melissa E Nagelin, Ph.D.,
Adan Cajina, Chief, Demonstration
will be inspected before being allowed on Scientific Review Officer, Office of Scientific
Evaluation Branch, Office of Training
campus. Visitors will be asked to show one Review/DERA, National Heart, Lung, and
and Capacity Development, Division of
form of identification (for example, a Blood Institute, 6701 Rockledge Drive, Room
HIV Domestic Programs, HIV/AIDS government-issued photo ID, driver’s license, 7202, Bethesda, MD 20892, 301–435–0297,
Bureau, HRSA, 5600 Fishers Lane, or passport) and to state the purpose of their nagelinmh2@nhlbi.nih.gov.
09N108, Rockville, MD 20857, Phone: visit. (Catalogue of Federal Domestic Assistance
(301) 443–3180, Email: acajina@ Information is also available on the Program Nos. 93.233, National Center for
hrsa.gov. Institute’s/Center’s home page: http:// Sleep Disorders Research; 93.837, Heart and
Dated: September 19, 2017. deainfo.nci.nih.gov/advisory/fac/fac.htm, Vascular Diseases Research; 93.838, Lung
George Sigounas, where an agenda and any additional Diseases Research; 93.839, Blood Diseases
information for the meeting will be posted and Resources Research, National Institutes
Administrator. of Health, HHS)
[FR Doc. 2017–20544 Filed 9–25–17; 8:45 am] when available.
(Catalogue of Federal Domestic Assistance Dated: September 20, 2017.
BILLING CODE 4165–15–P
Program Nos. 93.392, Cancer Construction; Michelle Trout,
93.393, Cancer Cause and Prevention Program Analyst, Office of Federal Advisory
DEPARTMENT OF HEALTH AND Research; 93.394, Cancer Detection and Committee Policy.
HUMAN SERVICES Diagnosis Research; 93.395, Cancer [FR Doc. 2017–20489 Filed 9–25–17; 8:45 am]
Treatment Research; 93.396, Cancer Biology BILLING CODE 4140–01–P
National Institutes of Health Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
National Cancer Institute; Notice of Cancer Control, National Institutes of Health, DEPARTMENT OF HEALTH AND
Meeting HHS) HUMAN SERVICES
Pursuant to section 10(d) of the Dated: September 20, 2017. National Institutes of Health
Federal Advisory Committee Act, as Melanie J. Pantoja,
amended, notice is hereby given of a Center for Scientific Review; Notice of
Program Analyst, Office of Federal Advisory
meeting of the Frederick National Committee Policy. Closed Meetings
Laboratory Advisory Committee to the
[FR Doc. 2017–20487 Filed 9–25–17; 8:45 am]
National Cancer Institute. Pursuant to section 10(d) of the
The meeting will be open to the BILLING CODE 4140–01–P Federal Advisory Committee Act, as
public, with attendance limited to space amended, notice is hereby given of the
available. Individuals who plan to following meetings.
attend and need special assistance, such The meetings will be closed to the
as sign language interpretation or other public in accordance with the
VerDate Sep<11>2014 18:28 Sep 25, 2017 Jkt 241001 PO 00000 Frm 00063 Fmt 4703 Sfmt 4703 E:\FR\FM\26SEN1.SGM 26SEN1](https://thefederalregister.org/doc/82_FR_45005/page/2.svg)
Document Created: 2017-09-26 02:48:17
Document Modified: 2017-09-26 02:48:17
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Action | Notice. | |
| Contact | Mr. Adan Cajina, Chief, Demonstration Evaluation Branch, Office of Training and Capacity Development, Division of HIV Domestic Programs, HIV/AIDS Bureau, HRSA, 5600 Fishers Lane, 09N108, Rockville, MD 20857, Phone: (301) 443-3180, Email: [email protected] | |
| FR Citation | 82 FR 44820 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR